核糖体蛋白L6在前列腺癌中的表达及临床意义

Expression and clinical significance of ribosomal protein L6 in prostate cancer

目的探讨核糖体蛋白L6(RPL6)在前列腺癌组织中的表达及临床意义。方法应用实时荧光定量PCR(RT-q PCR)和Western blot检测RPL6在前列腺癌组织(80例)及癌旁组织(62例)中的表达水平,分析RPL6 m RNA表达水平与前列腺癌患者的临床病理特征及预后之间的关系。结果 RPL6在前列腺癌组织中的表达水平明显高于癌旁组织(P<0.05);血清前列腺特异性抗原(PSA)值高、Gleason评分高、临床分期晚、有淋巴结转移患者的RPL6m RNA表达水平增高(均P<0.05),而不同年龄、精囊侵袭、血管侵犯及手术切缘阳性情况患者的RPL6 m RNA表达水平无明显差异(均P>0.05)。RPL6 m RNA高表达前列腺癌患者的术后无生化复发生存率较低(χ2=4.530,P=0.033)。结论 RPL6表达水平增高与前列腺癌的发生发展及不良预后相关;或可用其作为初步判断前列腺癌患者预后的肿瘤标志物。

Objective To explore the expression of ribosomal protein L6 （RPL6） in prostate cancer and its clinical sig- nificance. Methods RT-qPCR and Western blot assay were used to measure the mRNA transcription and protein expres- sion levels of RPL6 in prostate cancer tissues （n=80） and adjacent non-cancerous tissues （n=62）. The relationship between RPL6 mRNA expression level and clinicopathological factors of prostate cancer was statistically analyzed. Results The mRNA and protein expression levels of RPL6 were significantly higher in prostate cancer tissues compared with those of non-cancerous tissues （P 〈 0.05）. There were higher serum expression levels of prostate specific antigen （PSA） and higher Gleason score in prostate cancer tissues. The expression level of RPL6 mRNA was significantly higher in patients with lymph node metastasis and late clinical stage （P 〈 0.05）. There were no significant differences in PSA levels between different ages, with or without seminal vesicle invasion and different surgical margin status （P 〉 0.05）. Kaplan-Meier survival analysis of biochemical recurrence （BCR）-free survival time showed the significantly lower recurrent rate in patients with high RPL6 mRNA expression （X2=4.530,P=0.033）. Conclusion The elevated expression of RPL6 may play a role in the development of prostate cancer, and which can be used as a tumor marker to assess the prognosis of prostate cancer.